Morgan Carpenter. Reproductive Health Matters. Volume 24, Issue 47, 2016.
Introduction
Intersex people are born with sex characteristics that do not meet medical and social norms for female or male bodies. People with intersex variations are heterogeneous, with varied bodies, sexes, and sexual and gender identities. Intersex traits comprise “at least 40 different entities of which most are genetically determined”. Disclosed by a doctor to a parent or an individual, an “exact diagnosis is lacking in 10 to 80% of the cases”, including the author’s own medical papers which include the terms hypogonadism, gynaecomastia and indeterminate sex.
Between 0.5 and 1.7% of people may have intersex traits. Numbers are vague, not only due to diagnostic challenges and the growing impact of genetic selection, but also stigma. The consequences of being born with intersex characteristics are profound. Historicised as hermaphrodites, gods and monsters, visibly intersex people have been subjects of infanticide and freak shows. Dan Ghattas remarks that, everywhere in the world, people with intersex bodies have been deemed incapable of integration into society.
In a repeated historical pattern, terms have changed over the last century as clinical decision-makers have determined pre-existing language to be imprecise or pejorative: that affected persons are not hermaphrodites, not pseudo-hermaphrodites, not intersex, but disordered children whose bodies need finishing or disambiguating.
Human rights violations take various forms. In places without accessible medical systems, abandonment, infanticide, mutilation, and stigmatisation of children and their mothers may occur if an intersex trait is obvious. Recent cases include mutilation and murder of an adolescent in Kenya, and abandonment of an infant in Shandong, China. In places with accessible medical systems, human rights violations take place in medical settings, intended to make intersex bodies conform to narrow social norms for females or males. Lack of necessity, autonomy and valid consent mean that such “normalising” interventions violate “rights to health and physical integrity, to be free from torture and ill-treatment, and to equality and non-discrimination”.
Medicalisation
Intersex bodies became medicalised from the end of the 19th century, alongside the medicalisation of women’s bodies and of homosexuality. From the 1950s, a new belief in the malleability of infants’ gender identities brought an “optimal gender model” into being: intersex children identified at or close to birth could be “normalised” by aligning their bodies, gender roles and sex of rearing. Surgical limitations meant that most affected intersex infants were assigned female. “Successful” cases were heterosexuals, who identified with their assigned gender.
Sex assignment of infants diagnosed at birth is now typically based on visual inspection, genetic and hormonal testing. While there are some common rules, based on chromosomes and sensitivity and exposure to androgens, social attitudes favouring male children can influence assignments in some regions.
Sex “normalising” interventions, to reinforce a sex assignment, include feminising and masculinising surgical and hormonal interventions, and gonadectomies, often during infancy, childhood and adolescence, before the recipient can consent and without firm evidence of necessity or good surgical outcomes. However, initial sex assignment need not be reinforced, permanent, or irreversible.
In some cases, other interventions may be necessary for physical health, notably for endocrine issues in congenital adrenal hyperplasia. Surgical interventions may sometimes be necessary to tackle elevated gonadal cancer risks or urinary issues. These surgical interventions should not be contentious, but firm supporting data are lacking. Moreover, clinical decisions on these interventions entwine therapeutic with “normalising” non-therapeutic rationales.
Feminising interventions include clitoral surgeries (such as “clitoridectomies”), construction of a vagina, and related genital surgeries, for example, in infants and children with larger clitorises or ambiguous genitalia. Masculinising interventions include surgeries for “hypospadias”, diagnosed in boys when the urethra opens between the glans of the phallus and the perineum.
Clitoral cutting is considered female genital mutilation, an abhorrent and harmful practice, and a form of gender-based violence prohibited in many countries, yet exemptions may apply to intersex girls. Adults are also vulnerable: a medical journal reported in 2013 that four elite women athletes from low- and middle-income countries were discovered to have intersex traits during routine testosterone testing. They were subjected to “partial clitoridectomies” and sterilisation under duress, to enable their return to competition.
Vaginal construction necessitates regular post-surgical dilation by the insertion of an instrument; this may in some cases be experienced as rape. Follow-up examinations may include sensitivity testing on minors, such as with a cotton bud or vibrator.
Surgeries for hypospadias are typically undertaken in infancy, despite evidence that outcomes are not determinable until adulthood. Construction and maintenance of a urinary tube may involve multiple surgeries with significant impact on sensitivity, high complication rates and particularly poor long-term outcomes, and even genital “resurfacing”. Evidence of the necessity of early intervention is lacking.
Risks of gonadal cancer have been overstated or poorly evidenced, resulting in sterilisations. During a 2013 Australian Senate inquiry into the involuntary or coerced sterilisation of intersex people, it was revealed that routine sterilisations of women with complete androgen insensitivity syndrome no longer take place because of overstated risks. There has been no attempt at reparations for individuals who consequently need a lifetime of hormone replacement.
Solid data on the prevalence of “normalising” interventions are scarce but, despite media reports stating the contrary, interventions remain routine and central to the management of intersex traits. For example, although FGM is prohibited in the UK, Creighton et al note an increasing number of clitoral surgeries on under-14s in the UK; “it is not clear if this is secondary to an increase in the detection or incidence” of intersex traits. According to a 2015 neonatal handbook by the government of Victoria, Australia, an intersex birth event remains “distressing” for all in the delivery room; “[c]orrective surgery is usually undertaken within the first year of life”, despite contrary earlier ethical guidance by the same government.
Rationales and outcomes of medical intervention
Current medical protocols on the paediatric management of intersex traits were set out in the Chicago “consensus” statement in 2006. It framed intersex as “disorders of sex development”, recommending interventions to “minimise family concern and distress”, facilitate parental bonding and “mitigate the risks of stigmatisation”. The statement recommended caution on surgical treatment, but nevertheless facilitates such interventions. A 2016 follow-up statement does the same. The authoritativeness and “consensus” in the Chicago statement lies not in comprehensive clinician input or meaningful community input, but in its utility to justify any and all forms of clinical intervention. Clinical practices have not been impacted by the statement; they have been validated.
Local ethical guidelines, such as in Victoria, Australia, extend that framework, suggesting that medical interventions address cultural risks including “reduced opportunities for marriage”. A clinician submission to the Australian Senate inquiry recommended surgeries justified as therapeutic for “functional reasons such as to allow a male individual to urinate while standing, and for psychosocial reasons such as to allow the child to develop without the psychosocial stigma or distress which is associated with having genitalia incongruous with the sex of rearing”. These rationales express cultural norms, in much the same way as rationales for female genital mutilation.
In a clinician submission to the Australian Senate committee inquiry, rationales for sterilisation included “sex of rearing, estimated capacity of the gonad to produce hormones in accordance with or opposite to sex of rearing and/or (developing) gender identity, likelihood of gender dysphoria”. The committee was disturbed by this entanglement of different justifications.
The Australian Senate inquiry found in 2013 that psychosocial and cultural rationales for surgical interventions are a “circular argument that avoids the central issues”. A 2012 Swiss national bioethics report concluded that interventions addressing stigma, familial and social integration “run counter to the child’s welfare”.
There are only a few large quantitative data sources on outcomes, due in part to limited follow-up, a lack of comparative data on individuals who have avoided early intervention, and the low frequency of many intersex traits. These mean that there is little evidence to support either medical intervention or non-intervention. A decade after the Chicago Consensus statement, there are no credible alternative clinical pathways that avoid early surgical intervention.
A rhetoric of improved surgical techniques and outcomes has been evident for more than two decades, at least since 1995, without evidence. Lloyd et al in 2005 noted that evidence of benefit from early surgical interventions “is conspicuous by its absence”. A 2013 submission by the Royal Children’s Hospital Melbourne to the Australian Senate inquiry acknowledged that “outcomes related to current [surgical] practices remain to be established”. However, there is evidence of harm from early surgical practices: a submission by the Australasian Paediatric Endocrine Group identified “particular concern regarding sexual function and sensation” as a consequence of recommended surgeries. In the UK, Creighton et al remark that “a schism has developed between clinicians working in paediatric and in adolescent/adult services” due to lack of evidence of benefits from early surgeries. Clinical claims about improved surgical techniques are used to justify surgeries early in life, but surgical improvements over time should mean that surgeries on infants be deferred, so that consenting adults can later benefit from those improvements if they choose.
According to Lloyd et al, clinical decision-making on the necessity of genital surgeries can be “entirely subjective”. The 2013 Australian Senate inquiry found “no medical consensus around the conduct of normalising surgery” on intersex children. As noted by Liao et al, parents “may not realise that they are de facto opting for experimental surgery on their children” and so they are unable to provide valid consent; “parental regret can be high” for interventions aimed at tackling parental and social issues.
In addition to issues of sensation and sexual function, and the possibility of incorrect sex assignment, surgeries create physical differences that inhibit intimacy. Iain Morland, for example, describes being anatomically “both glaringly unusual and yet brutally normalised”. A clinical study of 439 intersex adults, children and parents of intersex children in Germany undertaken between 2005 and 2007 showed that 81% of adults and children with intersex traits had undergone surgeries related to those traits; two-thirds of adults linked sexual problems to those surgeries. A recent Australian survey of 272 adults born with atypical sex characteristics found “strong evidence” of “institutionalised shaming and coercive treatment”. Of the study population, 60% reported receiving medical interventions related to their intersex traits, and a majority experienced negative consequences, not simply medical or sexual: early school leaving (by 18% of respondents compared to a national average of 2%) was coincident with puberty and pubertal medical interventions.
Key ethical and human rights concerns with current medical practices are often portrayed as matters of surgical timing, degree of physical difference from sex norms, and sex assignment. The intersex movement poses more fundamental concerns of valid consent, self-determination and bodily autonomy.
The intersex movement
Intersex advocates have been active since the 1990s. The early establishment of Australian and UK Androgen Insensitivity Syndrome Support Groups was followed by the Intersex Society of North America (ISNA), a Latin American consortium, national groups and international networks.
In just a few years, ISNA moved from demonstrating outside a paediatric conference in 1996 to delivering a plenary address at the same conference. Medical authority was subsequently reasserted in the Chicago statement of 2006: an invite-only group led by US clinicians, with peripheral involvement by ISNA, changed clinical language from intersex to “disorders of sex development” (DSD). ISNA hoped this would open doors for closer collaboration with clinicians, and improved medical practices but instead it has led to greater biomedicalisation.
The shift to DSD never received widespread acceptance by intersex individuals, advocates and organisations; the term is regarded as pathologising and poorly translatable. A decade later, a survey of Australians born with atypical sex characteristics shows low acceptance of the term. Only 3% of respondents use DSD by choice, while 60% use terms including the word intersex. Interestingly, 21% use DSD when accessing healthcare, indicating a perceived need to use disordering language to obtain appropriate care.
The intersex movement of the mid-2000s divided acrimoniously between those accommodating to clinical leadership and those favouring human rights approaches. ISNA folded in 2008. Voices accommodating of clinical leadership have found themselves co-opted and disappointed.
The intersex human rights movement engages with international and national human rights and ethics institutions, engages in discussions with policy-makers, and demonstrations, and instigates legal action. Its core human rights goals are simple: the rights to bodily autonomy and self-determination, and an end to stigmatisation.
Human rights developments
Clinical practices have been scrutinised in a few countries. A 2012 national Swiss bioethics inquiry recommended substantive changes to clinical practice, to defer non-urgent treatments and recognise human rights norms, as did the 2013 Australian Senate inquiry. Neither has been implemented. In 2008, Christiane Völling won legal action following involuntary medical treatment at age 18 in Germany. Michela Raab won a similar case in Germany in 2015. In the US, the case of a child, MC, has been pursued since 2013 with no conclusion to date. Bauer and Truffer note that there have been no successful legal actions by intersex persons subjected to interventions during infancy or childhood, due in part to statutes of limitations, and claims of clinical consensus.
National legislation has begun to act on discrimination and bodily autonomy. South Africa first added intersex to the attribute of “sex” in discrimination law in 2005, through work by intersex and anti-apartheid activist Sally Gross. Australians secured an independent attribute of “intersex status” in discrimination law in 2013. In 2015, Malta became the first country to legally recognise the right of all individuals to “bodily integrity and physical autonomy”, adding a more encompassing attribute of “sex characteristics” to discrimination law, and prohibiting social, cultural and other unnecessary interventions on the sex characteristics of minors.
A series of International Intersex Forums took place between 2011 and 2013. Out of these came a landmark statement in Malta in 2013. This was followed in 2014 by a first submission to the World Health Organization, by advocates from six continents outlining concerns with the International Classification of Diseases (ICD).
Advances in international human rights forums have been made as a result of purposeful advocacy. In 2013, the UN Special Rapporteur on torture first acknowledged the existence and harmful consequences of irreversible, involuntary medical treatment to “fix” intersex children. In 2015, the Council of Europe’s Human Rights Commissioner first recognised the right of intersex people not to undergo sex assignment treatment. The same year, the Council of Europe, the European Union Agency for Fundamental Rights, and the Inter-American Commission for Human Rights called for the reassessment of medical classifications that pathologise intersex traits.
UN Treaty Bodies are now responding to these developments. The Committee against Torture has commented on early unnecessary and irreversible sex determining surgeries, consent and long-term impact in Switzerland, in China and in Hong Kong. The Committee on the Rights of the Child has commented on non-discrimination, right to identity and harmful practices in Chile, and harmful practices in France and Ireland. The Committee on the Rights of Persons with Disabilities has commented on protecting the integrity of the person in Germany. As a result of comments on Chile, in late 2015 the Chilean Health Ministry issued instructions suspending early medical interventions.
Zeid Ra’ad Al Hussein, UN High Commissioner for Human Rights, opened an intersex expert meeting in September 2015 stating:
“All human beings are born equal in dignity and rights… regardless of our sex characteristics.”
Policy disjunctions
Despite human rights advances, many challenges remain, not least in implementation of reforms to ensure that clinical practices meet human rights norms. Disjunctions are evident between social and medical policy and, in both domains, between rhetoric and reality. This disjunction differentiates between the medical treatment of “individuals with DSDs” and social policy advances for the intersex or broader LGBTI communities. Fundamentally, addressing DSD and intersex populations as separate is deeply flawed, and may even permit medical policy to disregard the intersex human rights movement.
For example, in 2014 an Australian territory introduced three additional birth sex classifications, in part considered suitable for intersex children. Communications between the author and the Territory’s chief/health minister on that policy and on the medical treatment of children elicited divergent, unrelated responses, drafted by different policy teams with different policy goals. The government was not able to create a well-formed policy because it does not possess a coherent understanding of the population affected. A similar bifurcation between DSD and intersex is evident in US medical schools. Distinctions between rhetoric and reality are evident in Victoria, Australia, where 2013 ethical guidelines on the care of children with intersex traits are ignored and contradicted by the same government’s current neonatal handbook materials on ambiguous genitalia and hypospadias. Revisions to those ethical guidelines are in hand, and these are likely to remove marriageability as a rationale for medical intervention, but the ethical guidelines are irrelevant to actual clinical practice.
Policy disjunctions extend to public resourcing. Australian genetic research on intersex traits is partially justified by “psychological trauma”, yet, no health services offer psychological support for adults. While peer and advocacy groups support intersex populations, they lack sufficient funding.
Disjunctions are also evident in media reporting. Reporters continue to contrast intersex perspectives with medical perspectives, typically those of paediatric endocrinologists or geneticists. Media reports frequently and uncritically present an unsubstantiated narrative of fewer surgical interventions, and improved medical practices. Reports that frame intersex within LGBTI contexts frequently, and incorrectly, often assume that intersex people are all gay, or transgender.
From an intersex perspective, the LGBT movement appears preoccupied with identity and relationship recognition, without recognition of bodily autonomy, and deeper challenges posed by sex and gender norms. Discussions within LGBT spaces may suggest that intersex groups do not want inclusion; some intersex-led organisations seek it, while others simply fear becoming overwhelmed and instrumentalised. Many “LGBTI” organisations treat intersex inclusion as an inconsequential goal, rather than a deliberate strategic process, resulting in a reality that fails to match the rhetoric of inclusivity. Regardless, aggregation of our issues is progressing, including in health, foreign policy, and human rights. If “LGBTI” is to work, it has to work for all constituent populations. Dan Ghattas suggests that LGBT organisations seeking to become inclusive should adopt the statement of the Third International Intersex Forum as a key first step.
In Australia, a shift from LGBT to LGBTI occurred early, but with little deliberate attention to its implications. The few institutions that have responded to “intersex status” in law have typically focused on the same issues of honorifics, pronouns and toilets that they address in responding to discrimination based on gender identity. This is troubling. Not only does this approach obscure issues of medicalisation and bodily autonomy, it treats intersex as no more than a gender identity issue.
In practice, intersex as identity is polymorphic, but asserts the dignity of stigmatised embodiment. The gender identities of intersex people may match sexes assigned at birth, or may not. As with transgender persons, intersex persons can suffer “misgendering”, a failure to acknowledge the validity of individuals’ gender identities. Uniquely, intersex people also face failures to acknowledge the validity of sexes assigned at birth.
Misconceptions often frame intersex as a third sex. For example, in 2015, an Australian State agency saw no contradiction in proposals simultaneously calling for a third sex classification and promoting intersex human rights via a poster stating “sex is a spectrum”. A Chilean LGBT group proposed a third sex for intersex infants in 2016, with similar proposals elsewhere.
Identities are frequently informed by bodily characteristics, but while some intersex people use intersex or non-binary as gender labels, most intersex adults are female or male. Suppositions that sex characteristics dictate gender identity not only deny the existence of trans people, they deny agency to intersex people to autonomously determine sex and gender. Third sex classifications pose added difficulties for infants: parents may feel increased pressure to avoid stigma, disclosure and social incomprehension through physical interventions, ensuring an unequivocal, familiar sex assignment. As Mauro Cabral comments, it is necessary to challenge and expand narrow definitions but also the reduction of intersex issues to matters of gender identity.
The statement of the Third International Intersex Forum calls for initial male or female assignment, recognising physical integrity, with openness to changes in sex assignments, and non-binary and multiple options for people able to consent. The statement also calls for the removal of sex and gender, like race and religion, from official documentation as a more universal, long-term policy goal.
Hermeneutical injustice
Underlying these policy disjunctions and misconceptions is a broader issue, described by philosopher Miranda Fricker as “hermeneutical injustice”; a form of injustice in knowing that prevents a person from making sense of their own lived experience due to a lacuna in social understanding. This arises due to the “relative powerlessness” of the subject’s social group. For intersex people, this hermeneutical injustice arises in two distinct ways: through clinical secrecy and terminology, and through societal discourse on identity.
Clinical secrecy was most profound from the 1950s: a deliberate culture of secrecy withheld diagnoses to “enable the child have a ‘normal’ physical and psychosexual development”. That silence gave people with intersex traits no words to describe our sutures, scars and lack of sensation, and no words to understand commonalities shared across the diversity of lives and histories. This culture changed with the introduction of DSD, but clinical language still prevents parental understanding of a child in positive, non-pathological ways, and the individualisation of each condition separates people from intersex communities. Morgan Holmes states that the shift to DSD, “reinstitutionalises clinical power to delineate and silence those marked by the diagnosis; … this silencing is precisely the point of the new terminology”.
Identity-focused language mischaracterises intersex human rights issues as matters of sexual orientation and gender identity. It prioritises issues of performativity and identity over deeper, more intractable issues of bodily autonomy. These act as barriers to familial and self-understanding, and to the social connectedness that can help individuals overcome stigma.
Conclusions
International human rights institutions have begun to address intersex human rights issues, acting on testimonies from a growing and decentralised global movement. While this progress is welcome, effective implementation of policy and change in clinical practice remain a priority. This means challenging an unsubstantiated rhetoric of changing clinical practice on one hand, and an inconsequential rhetoric of inclusion on the other.
Structural change is needed to end the pathologisation and stigmatisation of healthy intersex bodies. Current rhetoric of changed clinical practices demonstrates a focus on the appearance or optics of those practices; unsubstantiated claims of change must be evidenced. Harmful practices in medical settings must be eliminated; the right of intersex people not to undergo medical intervention for social and cultural reasons must be recognised, ensuring the right to make autonomous informed choices about irreversible treatments. The development of rights-based clinical pathways must be prioritised. Where individuals are unable to provide consent for necessary treatment, physical health issues need scrutiny, careful justification, and distinguishing from “normalising” cultural practices. Diagnoses in the International Classification of Diseases must change to ensure that treatments meet human rights norms.
Rhetorics of inclusion and a focus on performativity need to be challenged by human rights bodies and funders. Resourcing models that advance intersex-led initiatives need to be supported and extended. Above all, bodily autonomy, stigmatisation and medicalisation are human rights issues. Intersex-led advocacy and peer support groups must be at the heart of efforts to manage and resolve them.